128253-31-6|Veliflapon sodium|sodium (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetate|-范德生物科技公司

Veliflapon sodium

NMR下载 COA and HPLC MSDS下载
names：
sodium (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetate
CAS号：
128253-31-6
MDL Number：
MF(分子式)： C23H22NNaO3 MW(分子量)： 383.4228
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	sodium (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetate
英文别名	BAY-X1005; BAYX1005; BAY X1005; DG-031; DG 031; DG031; Veliflapon; Veliflapon sodium;
CAS号	128253-31-6
SMILES	O=C([O-])[C@H](C1CCCC1)C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2.[Na+]
Inchi	InChI=1S/C23H23NO3.Na/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19;/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26);/q;+1/p-1/t22-;/m1./s1
InchiKey	CSKPYCISCFHTLT-VZYDHVRKSA-M
分子式 Formula	C23H22NNaO3
分子量 Molecular Weight	383.4228
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Veliflapon sodium(CAS:128253-31-6 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Veliflapon, also known as BAY X 1005 and DG-031, is a leukotriene synthesis inhibitor. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. BAY-X1005 is a 5-lipoxygenase activating protein (FLAP) inhibitor. BAY-X1005 inhibits the synthesis of leukotrienes B4 and C4 in animal models and it inhibits synthesis of leukotriene B4 in A23187-stimulated leukocytes (IC50 values are 0.026, 0.039 and 0.22 μM for rat, mice and human leukocytes respectively).
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Roger P, Gascard JP, Bara J, de Montpreville VT, Brink C. MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005. Mediators Inflamm. 2001 Feb;10(1):33-6. PubMed PMID: 11324902; PubMed Central PMCID: PMC1781691.

[2]Nagai H, Takeda H, Uno T, Tanaka H, Matsuo A. Effect of a novel leukotoriene synthesis inhibitor, BAY x1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs. Prostaglandins. 1996 Feb;51(2):139-48. PubMed PMID: 8711135.

[3] Rossoni G, Sala A, Berti F, Testa T, Buccellati C, Molta C, Muller-Peddinghaus R, Maclouf J, Folco GC. Myocardial protection by the leukotriene synthesis inhibitor BAY X100

5: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Ther. 1996 Jan;276(1):335-41. PubMed PMID: 8558451.

[5] Hatzelmann A, Goossens J, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein. Biochem Pharmacol. 1994 Jun 15;47(12):2259-68. PubMed PMID: 8031320.

5: Gardiner PJ, Cuthbert NJ, Francis HP, Fitzgerald MF, Thompson AM, Carpenter TG, Patel UP, Newton BB, Mohrs K, Müller-Peddinghaus R, et al. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005. Eur J Pharmacol. 1994 Jun 2;258(1-2):95-102. PubMed PMID: 7925604.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开